Navigation Links
Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Date:11/29/2007

CAMBRIDGE, Mass., Nov. 29 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced the retirement of Steven C. Wheelwright, PhD from its Board of Directors and the addition of Robert Gay, PhD.

Dr. Wheelwright served as a Director at Merrimack since May 2006. He was recently named the President of Brigham Young University Hawaii and is stepping down due to his relocation. Most recently, Dr. Wheelwright served as a Baker Foundation Professor and Chairman of HBS Publishing at Harvard Business School, while serving on numerous boards including Merrimack.

"Steve was an invaluable resource for our Board and the management at Merrimack," said Gary Crocker, Chairman of Merrimack's Board of Directors. "He was an outstanding director that provided the Board and management with pharmaceutical and operations expertise. We congratulate him and wish him the best in his new position."

Dr. Gay joins Merrimack's board having served as the former Managing Director and Chairman of the Management Committee of Bain Capital. Bain Capital is one of the world's leading private equity firms with over $40 billion in capital with offices in the US, Asia and Europe. Prior to joining Bain, Dr. Gay held numerous high level positions including Executive Vice President of General Electric Credit Corporation's Capital Markets Group, Vice President in the Merchant Banking Group at Kidder Peabody, and Engagement Manager at the international consulting firm, McKinsey & Company.

"Bob Gay's extensive financial and management capabilities developed with leading companies such as Bain Capital and GE bring further experienced management perspective to our already distinguished board" said Mr. Crocker. "We are excited to have Bob on our team and feel that his insight from previous transactions, growth management, and organizational
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, owing to the launches of ... will increase more than sevenfold from $790 million ... the United States, France, Germany, Italy, Spain, the ... report entitled Atrial Fibrillation finds that ...
(Date:12/14/2009)... - Results From a Survey Conducted by ... Major Industrialized Countries , , - A ... impacts their enjoyment of the ... arthritis find shopping for gifts, ... difficult to do, ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2
... Enoch, S. Guenneau and A.B. Movchan , ... building stronger ocean-based structures to withstand tsunamis, it ... disappear. A collaboration of physicists from the Centre ... Universite in France and the University of Liverpool ...
... PharmAthene, Inc.,(Amex: PIP ), a biodefense company ... today that the National,Institute of Allergy and Infectious ... (NIH), has awarded the Company a multi-year contract,for ... a third generation,recombinant protective antigen (rPA) anthrax vaccine., ...
... and VERNON HILLS, Ill., Sept. 26 ,Winston Laboratories, ... of products for pain management, and Getting Ready ... GTRY), completed,a merger on September 25, 2008, pursuant ... Winston with and into Winston Acquisition Corp., a,wholly-owned ...
Other Biology Technology:Tsunami invisibility cloak, dark energy v. the void, sorting nanotubes with light, and more 2Tsunami invisibility cloak, dark energy v. the void, sorting nanotubes with light, and more 3PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 2PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 3PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 4PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 5PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 6Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger 2Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger 3Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger 4
(Date:12/14/2009)... diseases can be transmitted by sneezing, touching, or ... face, a habit that may have driven the dinosaurs ... , Jacqueline Upcroft, a member of f1000 Biology, highlights ... published in PLoS One. This led them to deduce ... diseased jaw bones seen in many tyrannosaurid fossils. , ...
(Date:12/14/2009)... 2009If you are spending the holidays with big Uncle ... would be better off with another family, spare a ... research team from McMaster University and the University of ... species that lives in groups, members make strategic decisions ... in the current issue of Biology Letters . ...
(Date:12/14/2009)... Nations Framework Convention on Climate Change taking place ... ,Bend the Trend, event on Sunday evening to ... the screening of the new ,Environmental Atlas of ... joint project of the European Environment Agency (EEA), ... a series of short films showing the significance ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 13711 1Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 13711 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 13711 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 13711 4Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 1Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 2Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 3
... Cellulose--a fibrous molecule found in all plants--is the ... also a favored target of renewable, plant-based biofuels ... about how plant cells synthesize individual cellulose fibers. ... Department of Plant Biology and Stanford University describes ...
... engineering at New Jersey Institute of Technology (NJIT) who is ... two grants that will help her bring the promise of ... , Arinzeh received a $700,000 grant from the New ... funds spinal cord research. She will use the grant to ...
... When medics are treating trauma patients, every second counts. ... it difficult to locate veins and administer lifesaving drugs ... Institute of Technology researchers is developing an inexpensive, handheld ... quickly. , "Depth and angle are the critical ...
Other Biology News:Formation of cellulose fibers tracked for the first time 2NJIT engineer poised to take stem cell research a step forward 2NJIT engineer poised to take stem cell research a step forward 3Researchers develop portable 'vein finder' for faster, more accurate injections 2Researchers develop portable 'vein finder' for faster, more accurate injections 3
NPT1 (M-19)...
... These versatile vacuum cups provide ... smooth, curved, or irregular surfaces. ,PFG: ... Short Bellows cup ,PCG: Multiple Bellows ... typically from 25 to 200 mm ...
8 different frozen tissues are mounted on positively charged glass slides...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Biology Products: